Sesamol combats diabetogenic effects of atorvastatin through GLUT-4 expression and improved pancreatic viability

© King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law..

Statin-associated diabetes (SAD) is an issue that has come to light after a series of recent clinical trials that has led to the issue of a black box warning for statins by the US FDA. However, the benefit of statin outweighs its risk. Nevertheless, experiments have been conducted to identify the mechanism by which statins aggravate the risk of diabetes only in a select population who bear the risk factors of obesity, sedentary lifestyle, hypertension, and other associated risk factors of lifestyle disorders. In this study, the possibility of utilization of a phyto-molecule, sesamol, for its ability to combat statin-associated diabetes using atorvastatin as the agent of choice has been explored. MMP assay and western blot was conducted to investigate the effects of atorvastatin on apoptotic cascade with sesamol as a protective agent was conducted in MIN-6 cells. Effect of the combination was tested in L6 cells with 2-NBDG uptake assay and as well as western blot for GLUT-4. A diet-induced hypercholesterolemia model was developed in an in vivo model animals and treated with atorvastatin and sesamol with histopathological analysis being carried out to evaluate the apoptotic markers and GLUT-4 presence. It was found that sesamol can combat pancreatic beta cell apoptosis via the internal apoptotic pathway activated by atorvastatin. With regards to muscle cells, sesamol could improve the GLUT-4 vesical production, but not improve glucose uptake which is inhibited by atorvastatin. These findings are further confirmed by animal studies. These findings indicate that sesamol can serve as a prototype molecule for further development and investigation of similar compounds to tackle SAD.

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:13
Enthalten in:	3 Biotech - 13(2023), 11 vom: 23. Nov., Seite 377

Sprache:	Englisch

Beteiligte Personen:	Keni, Raghuvir [VerfasserIn] Nayak, Pawan Ganesh [VerfasserIn] Kumar, Nitesh [VerfasserIn] Kishore, Anoop [VerfasserIn] Alnasser, Sulaiman Mohammed [VerfasserIn] Begum, Farmiza [VerfasserIn] Gourishetti, Karthik [VerfasserIn] Nandakumar, Krishnadas [VerfasserIn]

Links:	Volltext

Themen:	Atorvastatin Drug-induced diabetes Journal Article New-onset diabetes Statin

Anmerkungen:	Date Revised 05.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE

doi:	10.1007/s13205-023-03784-9

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM363778225